Immunostaining showed the estrogen receptor (ER)/progesterone receptor (PR) subtype in 43 patients (53.1%), HER2 subtype in 18 patients (22.2%), and triple-negative breast cancer (TN) subtype in 20 patients (24.7%). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.